Brokerages expect ABIOMED, Inc. (NASDAQ:ABMD) to post sales of $163.84 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for ABIOMED’s earnings. The highest sales estimate is $164.10 million and the lowest is $163.50 million. ABIOMED posted sales of $124.68 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 31.4%. The business is scheduled to issue its next quarterly earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that ABIOMED will report full-year sales of $163.84 million for the current financial year, with estimates ranging from $582.80 million to $586.05 million. For the next financial year, analysts expect that the company will report sales of $745.13 million per share, with estimates ranging from $733.60 million to $757.16 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for ABIOMED.

How to Become a New Pot Stock Millionaire

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.20. The business had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The company’s revenue was up 34.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 EPS.

Several equities analysts have recently weighed in on ABMD shares. BidaskClub lowered ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Jefferies Group lifted their price objective on ABIOMED from $208.00 to $220.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 price objective on the stock in a research note on Friday, December 29th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. Finally, Leerink Swann lifted their price objective on ABIOMED from $200.00 to $265.00 and gave the company an “outperform” rating in a research note on Friday, January 19th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $288.86.

ABIOMED (ABMD) traded up $2.68 during midday trading on Friday, hitting $295.85. The stock had a trading volume of 333,504 shares, compared to its average volume of 501,827. The firm has a market cap of $13,100.00, a price-to-earnings ratio of 120.26, a P/E/G ratio of 4.06 and a beta of 0.25. ABIOMED has a fifty-two week low of $117.36 and a fifty-two week high of $304.28.

In related news, VP Andrew J. Greenfield sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total transaction of $5,407,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.00% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. State of Tennessee Treasury Department acquired a new position in ABIOMED during the 3rd quarter worth approximately $5,058,000. Pratt Collard Advisory Partners LLC acquired a new position in ABIOMED during the 4th quarter worth approximately $412,000. Hamilton Lane Advisors LLC lifted its position in ABIOMED by 50.8% during the 4th quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock worth $4,356,000 after acquiring an additional 7,827 shares in the last quarter. Swiss National Bank lifted its position in ABIOMED by 2.4% during the 4th quarter. Swiss National Bank now owns 71,300 shares of the medical equipment provider’s stock worth $13,362,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in ABIOMED by 46.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after acquiring an additional 919 shares in the last quarter. 88.42% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “$163.84 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2018/03/14/163-84-million-in-sales-expected-for-abiomed-inc-abmd-this-quarter.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.